Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster weight loss drug Zepbound was not dragging down sales. Pfizer sales ...

Oct 27 (Reuters) - Eli Lilly (LLY.N), opens new tab expects to start selling its weight-loss drug in Hong Kong as early as ...

(Reuters) -Eli Lilly expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday. The drugmaker has received approval from the ...

Eli Lilly (LLY) is planning to advertise its blockbuster weight-loss drug, Zepbound ... Company David Ricks speaks at the Economic Club of New York on March 12. (Spencer Platt/Getty Images ...

It also has another pill, amycretin. A phase 1 trial of amycretin released in September showed promising results. Meanwhile, Eli Lilly has orforglipron, an oral GLP-1 in phase 3. At the Seeking ...

Eli Lilly (LLY) is planning to advertise its blockbuster weight-loss drug, Zepbound ... including the diabetes medication Mounjaro. Lilly's new CFO, Lucas Montarce, said the company has much ...

It seems like every day a new study emerges linking Ozempic and similar drugs to new health benefits. Ozempic is part of a drug class known as GLP-1 medications, which mimic gut hormones that help ...

(Reuters) -Eli Lilly expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday. The drugmaker has received approval from the Hong ...

Investing.com -- Eli Lilly & Co. (NYSE ... potentially becoming the first drug of its kind available in the broader China region, Bloomberg News reported on Sunday. The report said that the ...

Eli Lilly (LLY) is planning to advertise its blockbuster weight-loss drug, Zepbound, for the first time next month ... Ad play: CEO of Eli Lilly and Company David Ricks speaks at the Economic Club of ...